Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota Authors: Junying Pan, Liying Yang, Haoyu Wang, Yinghua Chen Published: 2026 ABSTRACT AbstractImmune checkpoint inhibitors (ICIs) face challenges of drug resistance and immune-related adverse events (irAEs). Traditional Chinese medicine (TCM)—including single herbs, compounds, and active monomers—enhances ICI efficacy and reduces toxicity by remodeling the tumor immune microenvironment, regulating gut microbiota, and modulating key immune pathways. TCM also alleviates ICI-induced colitis and myocarditis, demonstrating the value of holistic and syndrome-differentiated therapy. Future research should clarify synergistic mechanisms to advance precise integration of TCM and ICI immunotherapy. Introduction Cancer immunotherapy marks a significant advancement in oncology. Immune checkpoint inhibitors (ICIs) activate T cell-mediated anti-tumour immune responses by blocking inhibitory signalling pathways, such as CTLA-4 and PD-1/PD-L1. This mechanism has notably improved survival outcomes for patients with various malignancies, establishing ICIs as a cornerstone of cancer treatment1,2. Nonetheless, their clinical application encounters two primary challenges. First, primary or acquired drug resistance results in a limited objective response rate, preventing a substantial proportion of patients from benefiting. Second, immune-related adverse events (irAEs), which can affect multiple organs, including colitis, pneumonitis, and myocarditis, may be life-threatening and significantly hinder the widespread application and long-term efficacy of ICIs3,4. Traditional Chinese Medicine (TCM) is utilised in various forms for cancer treatment, primarily categorised into three groups. The first category consists of single herbal medicines, such as Astragalus membranaceus and Ganoderma lucidum, for which research on mechanisms of action is relatively concentrated. The second category includes traditional compound decoctions, like Huang-Lian-Jie-Du Decoction and Shenmai Injection, which exemplify the holistic regulatory characteristics of TCM through their “multi-component, multi-target” effects. The third category encompasses modern active monomers extracted from Chinese herbs, including berberine and ginsenoside Rg1, which possess well-defined targets and have undergone more extensive mechanistic studies. These three categories of TCM exhibit significant differences in their pharmacologically active substance basis, mechanisms of action, and levels of clinical evidence. Consequently, when investigating their synergistic and attenuating mechanisms in conjunction with immune checkpoint inhibitors, it is essential to systematically review and elucidate each category separately. The challenges of resistance and toxicity associated with immune checkpoint inhibitors (ICIs) arise from the intricate and systemic nature of tumour-immune interactions. Conventional single-target blockade strategies often fail to adequately modulate the immunosuppressive network within the tumour microenvironment (TME) and to restore systemic immune homeostasis5. In this regard, Traditional Chinese Medicine (TCM), which is guided by the principles of a “holistic view” and “treatment based on syndrome differentiation”, offers distinct therapeutic advantages. TCM theory suggests that the development and progression of tumours are attributable to an internal deficiency of vital energy (Zhengqi), organ dysfunction, and the accumulation of pathogenic toxins. Treatment focuses on “reinforcing healthy energy and eliminating pathogens” (Fuzheng Quxie), which entails the synergistic actions of multiple components, targets, and pathways to systematically regulate the body’s immune state and restore balance in the internal environment6,7. This approach provides innovative perspectives and strategies for overcoming the limitations of ICIs. Recent research has established that Chinese herbal medicines and their active components can enhance the anti-tumour efficacy of immune checkpoint inhibitors (ICIs) and reverse resistance through various multidimensional mechanisms. These mechanisms include reshaping the tumour microenvironment (TME) by promoting immune cell infiltration, alleviating hypoxia, and inhibiting abnormal angiogenesis. They also involve modulating gut microbiota homeostasis and directly influencing immune checkpoint expression8,9. Furthermore, due to their inherent anti-inflammatory, antioxidant, and organ-protective properties, traditional Chinese medicine (TCM) has shown significant potential in preventing and alleviating immune-related adverse events (irAEs) induced by ICIs10. These findings suggest that the combined use of TCM and ICIs may yield a synergistic effect characterised by “enhancing efficacy and reducing toxicity”, thereby expanding the therapeutic window of cancer immunotherapy. It is important to recognise that, although the tumour microenvironment and the gut microbiota represent distinct research domains—where the former acts as the direct cellular target of drug action and the latter functions as a remote bioactive regulatory hub mediating therapeutic effects—these two dimensions are not isolated or parallel mechanistic pathways. Instead, they are systematically interconnected through the “microbiota-metabolite-immune” axis. Traditional Chinese medicine (TCM), due to its multi-component and multi-target holistic regulatory properties, simultaneously influences the local tumour immune microenvironment and gut microbiota homeostasis, thereby synergistically enhancing the efficacy of immune checkpoint inhibitors. This article systematically reviews the current research evidence and molecular mechanisms related to the role of traditional Chinese medicine (TCM) in enhancing the efficacy of immune checkpoint inhibitors (ICIs) and mitigating their toxic side effects. By summarising recent advancements in how TCM regulates the tumour microenvironment (TME), intervenes in immune signalling pathways, modulates the microbiota, and synergistically reduces toxicity in conjunction with ICIs, this review aims to offer theoretical insights and practical guidance for developing precision immunotherapy strategies that integrate both Chinese and Western medicine. Limitations in the clinical application of ICIs Analysis of resistance mechanisms Despite the significant advancements made by immune checkpoint inhibitors (ICIs) in treating various malignancies, their clinical efficacy is markedly limited by the widespread issue of drug resistance. Resistance can be classified into three categories based on the timing and mechanism of onset: primary (initial non-response), acquired (loss of response following initial efficacy), and adaptive (dynamic tumour escape) resistance11. Among these categories, acquired resistance is particularly prevalent; for example, its incidence may exceed 50% in patients with advanced non-small cell lung cancer undergoing monotherapy with PD-1/PD-L1 inhibitors12. The complexity of resistance mechanisms primarily arises from the intrinsic immune evasion strategies employed by tumour cells and the inhibitory microenvironment they create. Tumour immune escape involves a range of intrinsic and extrinsic mechanisms. At the intrinsic level of tumour cells, this phenomenon is primarily characterised by a low tumour mutational burden or defects in antigen presentation, which impede immune cell recognition13; aberrant activation of oncogenic signalling pathways, such as Wnt/β-catenin and MAPK, which suppress T cell recruitment and function14; and sustained high expression of PD-L1, which directly inhibits T cell activity15. At the level of the tumour microenvironment (TME), immune escape is largely defined by the infiltration and expansion of immunosuppressive cells, including regulatory T cells and M2-type tumour-associated macrophages, as well as the accumulation of immunosuppressive molecules, such as IDO1, CD73, and adenosine. Together, these factors create an immunosuppressive niche that diminishes the efficacy of immune checkpoint inhibitors (ICIs) 16,17. Intrinsic mechanisms of tumour cells involve various factors, including endogenous biomarkers such as tumour mutational burden (TMB) and microsatellite instability (MSI), which are critical in the development of resistance to immune checkpoint inhibitors (ICIs). Tumour mutational burden indicates the total number of mutations present in tumour cells. A high TMB is generally associated with an increased number of neoantigens, thereby enhancing immune recognition. Nevertheless, some tumours with elevated TMB can evade T-cell attack through mechanisms such as defective antigen presentation or compensatory upregulation of immune checkpoints, resulting in primary or acquired resistance17. The status of microsatellite instability directly affects tumour sensitivity to PD-1/PD-L1 inhibitors. Tumours exhibiting high microsatellite instability (MSI-H), which arise from deficient mismatch repair that produces numerous frameshift mutations, typically demonstrate favourable responses to ICIs. In contrast, microsatellite-stable (MSS) tumours, characterised by low mutational burden and inadequate immune infiltration, frequently show resistance to ICIs17. These endogenous biomarkers not only facilitate a more comprehensive molecular characterisation of resistance mechanisms but also provide a rationale for selecting targeted interventions with traditional Chinese medicine (TCM), such as modulating immune recognition, enhancing antigen presentation, and reshaping immune infiltration. Immune-related adverse events (irAEs) Immune checkpoint inhibitors (ICIs) enhance anti-tumour immunity by disrupting immune checkpoints; however, this activation can also provoke excessive immune responses, leading to attacks on normal tissues and a range of immune-related adverse events (irAEs). These irAEs can impact nearly every organ system, presenting with highly variable clinical manifestations. Common examples include skin rash, colitis, pneumonitis, hepatitis, and endocrinopathies18. The onset of irAEs is associated with the disruption of immune checkpoints’ physiological role in maintaining peripheral immune tolerance, potentially involving T cells, autoantibodies, and inflammatory cytokines19. Among these immune-related adverse events (irAEs), serious conditions such as myocarditis and encephalitis exhibit a relatively low incidence, typically <1%. However, their fatality rates are alarmingly high, reaching up to 50% and over 19%, respectively, thereby posing a significant threat to clinical safety20,21. Moreover, the risk of developing irAEs is closely associated with the immune checkpoint inhibitor (ICI) treatment regimen. Research indicates that both the severity and incidence of irAEs are dose-dependent22. Simultaneously, the combination of ICIs with chemotherapy, targeted therapy, or dual immune checkpoint inhibitors (e.g. anti-CTLA-4 combined with anti-PD-1) may enhance therapeutic efficacy but also markedly increases the risk of high-grade irAEs. For instance, combination therapy significantly elevates the reported rates of hypophysitis and colitis, among others23,24. Consequently, while striving for maximal efficacy, the management and mitigation of irAEs remain an unavoidable challenge in clinical practice, as shown in Figure 1. Schematic overview of the dual role of traditional Chinese medicine (TCM) in enhancing the efficacy of immune checkpoint inhibitors (ICIs) and mitigating immune-related adverse events (irAEs). The left panel illustrates that TCM enhances ICI efficacy by remodelling the tumour microenvironment (TME) and regulating gut microbiota, which promotes T cell-mediated antitumor immunity. The right panel demonstrates that TCM alleviates ICI-induced irAEs, such as colitis, myocarditis, and other organ toxicities, through anti-inflammatory, antioxidant, and organ-protective mechanisms. Key TCM interventions (e.g. Shenmai injection, Huangqin Tang, berberine) and their primary targets (e.g. HIF-1α, PD-L1, gut microbiota-derived metabolites) are indicated. This figure underscores the “enhance efficacy and reduce toxicity” paradigm of TCM as an adjunct to ICI therapy. Mechanisms of action of traditional Chinese medicine in enhancing the efficacy of ICIs Traditional Chinese Medicine (TCM) operates not through a singular target but by utilising its systemic regulatory advantage characterised by “multi-component, multi-target, multi-pathway” interactions to generate synergistic effects with Immune Checkpoint Inhibitors (ICIs). The mechanisms that enhance its efficacy primarily focus on two core aspects. First, TCM directly reshapes the tumour immune microenvironment (TME) by promoting immune cell infiltration and function, improving hypoxia, inhibiting abnormal angiogenesis, and targeting immune checkpoint signalling pathways. This process reverses the immunosuppressive state and enhances T cell anti-tumour activity8,25. Second, TCM indirectly regulates gut microbiota homeostasis by altering the composition of specific microbial populations and their metabolites, which affects systemic immune responses and consequently improves therapeutic responses to ICIs while overcoming resistance26,27. These two mechanisms are interrelated and together form a “microbiota-immune-metabolism” network, thereby providing a robust scientific foundation for the combined application of TCM and ICIs28. The mechanisms by which traditional Chinese medicine (TCM) enhances the efficacy of immune checkpoint inhibitors (ICIs) can be understood through two interrelated dimensions. The first dimension involves the direct modulation of the tumour immune microenvironment, which represents the primary cellular target of drug action. By reshaping the composition and functional status of local immune cells, TCM effectively reverses immunosuppression. The second dimension pertains to the indirect regulation of gut microbiota homeostasis, which serves as a bioactive regulatory hub mediating therapeutic effects. Through the “microbiota-metabolite-immune” axis, TCM influences systemic immune responses. These two dimensions are not merely parallel or independent; rather, they are intricately functionally coupled through metabolite signalling molecules, collectively forming a systemic mechanistic network that enhances ICI efficacy. Regulating the tumor immune microenvironment The tumour immune microenvironment constitutes a complex ecosystem comprising three fundamental components: tumour cells, tumour stromal elements, and immune cells. The interactions among these components collectively influence the effectiveness of immune checkpoint inhibitors (ICIs). Traditional Chinese medicine (TCM) can modulate these three cell populations through multi-target and multi-pathway strategies, thereby reshaping the immune microenvironment to enhance ICI efficacy. This section will systematically elucidate the mechanisms of TCM action from three perspectives: ① direct effects on tumour cells to inhibit immune evasion; ② regulation of tumour stromal components to enhance the physical barrier and metabolic microenvironment; and ③ modulation of immune cells to promote antitumor immune responses and counteract immunosuppression. Promoting immune cell infiltration and activation Traditional Chinese medicine can significantly enhance the efficacy of immune checkpoint inhibitors (ICIs) by specifically modulating immune cell networks within the tumour microenvironment (TME). This modulation facilitates the infiltration and functional activation of various antitumor immune cells, including natural killer (NK) cells, dendritic cells (DCs), and T cells. For instance, studies involving Shengqi Injection (SMI) demonstrate that its combination with PD-1 inhibitors produces significant synergistic antitumor effects in non-small cell lung cancer (NSCLC) mouse models. This is evidenced by notably reduced tumour volume and weight in lung cancer (LLC) C57BL/6 mice, as well as markedly improved survival rates in the combination therapy group compared to the PD-1 monotherapy group (combination group 77.8% vs. PD-1 group 22.2%). In humanised NCI-H226 squamous cell carcinoma mouse models, 50% of mice in the combination therapy group achieved long-term survival, while none survived in the PD-1 monotherapy group. Furthermore, the combination therapy did not induce significant immune-related adverse events (e.g. hepatitis, pneumonia), and liver function markers (ALT, AST) remained within normal ranges. At the molecular level, single-cell RNA sequencing revealed that SMI (administered via intraperitoneal injection at a dosage of 0.02 mL/g daily, equivalent to the maximum clinically relevant dose, containing 1.38 mg total ginsenosides per mL) in conjunction with the PD-1 inhibitor significantly remodelled the tumour immune microenvironment. This phenomenon was primarily evidenced by a significant increase in the proportion of GZMAhigh NK and XCL1high NK cell subsets within tumour tissues, which are characterised by their robust secretion of cytotoxic and chemotactic factors. GZMAhigh NK cells exhibit high expression levels of granzyme, perforin, and death receptor ligands such as FASLG and TNFSF10. These cells engage with tumour cell subpopulations expressing NNMT+ and FSTL1+ through TNFSF10-TNFRSF11B and FASL-FAS ligand-receptor interactions, thereby inducing apoptosis in tumour cells. Simultaneously, combination therapy markedly reduced the infiltration of exhausted NKT cells and M2 tumour-associated macrophages (e.g. CXCL8+ Mø, MMP12+ Mø), which contributed to the alleviation of the immunosuppressive microenvironment. This finding confirms that SMI enhances PD-1 inhibitor-mediated antitumor immune responses by promoting the infiltration of NK cell subsets with potent cytotoxic and chemotactic capabilities, suggesting that NK cells may serve as a critical target for combination immunotherapy29. Traditional Chinese medicine formulas can activate innate immune signalling pathways, promoting dendritic cell (DC) maturation and T cell recruitment. Research indicates that Huanglian Jiedu Decoction (HLJD, 13.5 g/kg/d via oral administration) combined with PD-1/CTLA-4 inhibitors (10 + 5 mg/kg, intraperitoneal injection) significantly suppresses tumour growth and prolongs survival in a B16F10 melanoma mouse model. Mechanistic studies reveal that HLJD upregulates TLR7/8 expression by 1.45-fold and 1.24-fold, respectively, activates downstream type I interferon signalling pathways, elevates IFN-α levels, and enhances IRF7 expression. Additionally, HLJD increases reactive oxygen species (ROS) levels within tumour tissues. This mechanism facilitates dendritic cell maturation and antigen presentation, resulting in significantly increased infiltration of CD4+ and CD8+ T cells in tumour tissues, thereby enhancing the antitumor immune response30. Collectively, these findings demonstrate that traditional Chinese medicine can multidimensionally and multi-targetedly reshape the immune cell landscape within the tumour microenvironment (TME), providing a crucial mechanism for overcoming immune checkpoint inhibitor resistance. Regulation of the phenotypic transition and polarisation of immunosuppressive cells In the tumour immune microenvironment, the extensive infiltration of immunosuppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumour-associated macrophages (TAMs), significantly contributes to resistance against immune checkpoint inhibitors (ICIs). Active components of traditional Chinese medicine (TCM) can specifically induce the phenotypic transition and polarisation of these cell populations through multi-target interventions, thereby reversing the immunosuppressive state. Regulation of regulatory T cells (Tregs) Regulatory T cells (Tregs) suppress the antitumor activity of effector T cells through the secretion of inhibitory cytokines, including IL-10 and TGF-β. Research indicates that active components of traditional Chinese medicine (TCM) can effectively inhibit both the recruitment and function of Tregs. For instance, berberine significantly reduces the proportion of tumour-infiltrating Tregs in tumour-bearing mouse models, a mechanism closely linked to the inhibition of phosphorylation in the STAT3 signalling pathway and the downregulation of FoxP3 expression31. Additionally, ginsenoside Rg1 inhibits Treg differentiation by modulating the PI3K/AKT signalling pathway while concurrently promoting the activation and proliferation of CD8+ T cells, thereby restoring immune balance32. Regulation of myeloid-derived suppressor cells (MDSCs) Myeloid-derived suppressor cells (MDSCs) represent a critical immunosuppressive cell population within the tumour microenvironment, where they inhibit T cell function through the production of reactive oxygen species (ROS), reactive nitrogen species (RNS), and arginase. Active components of traditional Chinese medicine (TCM) have been shown to effectively induce the differentiation of MDSCs into a mature phenotype, thereby diminishing their immunosuppressive activity. Research indicates that Ganoderma lucidum polysaccharides significantly reduce the accumulation of MDSCs in the spleen and tumour tissue of tumour-bearing mice, a process that involves the downregulation of COX-2 and PGE2 expression as well as the inhibition of STAT3 signalling pathway activation33. In contrast, curcumin restores T cell proliferation capacity and enhances antitumor immune responses by inducing MDSC apoptosis and promoting their polarisation towards an M1-like macrophage phenotype34. Regulation of tumour-associated macrophage (TAM) polarisation In the tumour microenvironment, tumour-associated macrophages predominantly display an M2-polarized state that facilitates tumour progression and immunosuppression. Active components of traditional Chinese medicine (TCM) can effectively induce the polarisation of tumour-associated macrophages (TAMs) from the M2 to the M1 phenotype, thereby reversing their immunosuppressive function. For instance, polysaccharides derived from A. membranaceus promote macrophage polarisation towards the M1 phenotype by activating the TLR4 signalling pathway, which increases the secretion of TNF-α and IL-12 while downregulating the expression of M2 markers such as Arg-1 and IL-1035. Additionally, salvianolic acid B inhibits the STAT6 and PPAR-γ signalling pathways, thereby blocking macrophage polarisation towards the M2 phenotype and promoting their conversion to the M1 phenotype, which enhances T cell infiltration and activation. In summary, the active components of traditional Chinese medicine systematically counteract the immunosuppressive state of the tumour immune microenvironment by regulating the phenotypic transition and polarisation of regulatory T cells, myeloid-derived suppressor cells, and tumour-associated macrophages through multiple pathways. These findings offer significant intervention targets and a mechanistic foundation for addressing resistance to immune checkpoint inhibitors. Improving tumor hypoxia Tumour hypoxia represents a critical characteristic of the solid tumour microenvironment. By stabilising the expression of hypoxia-inducible factor-1α (HIF-1α), it initiates a cascade of adaptive responses that facilitate tumour progression and immunosuppression36. The hypoxic environment not only directly impedes the infiltration and functionality of cytotoxic T lymphocytes but also fosters the accumulation of immunosuppressive cells, including regulatory T cells and myeloid-derived suppressor cells, thereby diminishing the effectiveness of immune checkpoint inhibitors (ICIs) 37. Consequently, mitigating tumour hypoxia is regarded as a vital strategy for enhancing responses to cancer immunotherapy. Research indicates that active components of traditional Chinese medicine (TCM) can directly alleviate tumour hypoxia by targeting the HIF-1α signalling pathway, thus reversing the immunosuppressive microenvironment. For instance, in a triple-negative breast cancer model (MDA-MB-231), cardamonin downregulates HIF-1α and its downstream targets, PDHK1 and LDHA, by inhibiting the mTOR/p70S6K pathway. This action suppresses glycolysis, promotes mitochondrial oxidative phosphorylation, increases reactive oxygen species (ROS) accumulation, and induces apoptosis in tumour cells, ultimately inhibiting tumour growth. In vivo experiments demonstrated that cardamonin (3 mg/kg/d, administered via intraperitoneal injection) significantly reduced tumour volume and weight, downregulated HIF-1α and CD31 expression, and did not significantly affect body weight38. Beyond individual monomers, various active components of traditional Chinese medicine (TCM) and their compound formulations can alleviate tumour hypoxia by modulating HIF-1α and its downstream pathways. Research indicates that silibinin induces autophagic cell death in HepG2 cells by upregulating BNIP3 expression. Platycodin D also increases BNIP3 expression, leading to mitochondrial swelling and a decline in membrane potential, which promotes apoptosis in tumour cells. Additionally, ginsenosides activate BNIP3-mediated autophagic cell death39. Fuzheng Yiyong Decoction, which contains A. membranaceus polysaccharides among other ingredients, enhances the expression of BNIP3, Beclin-1, and LC3, thereby inducing autophagic apoptosis in hepatocellular carcinoma (HCC) cells. Clinical studies demonstrate that this decoction reduces the three-year recurrence rate and improves survival in patients with HCC following surgery40. Jiedu Xiaozheng Formula downregulates HIF-1α expression, suppresses glycolysis, and inhibits the proliferation of HCC cells. The combination of Huoxue Huayu Formula with XELOX chemotherapy results in decreased serum HIF-1α levels and enhanced immune function in patients with advanced HCC41,42. Collectively, these studies illustrate that TCM enhances the hypoxic tumour microenvironment through multi-target regulation of the HIF-1α signalling network, thereby providing a crucial mechanistic foundation for improving the efficacy of immune checkpoint inhibitors. Inhibiting abnormal angiogenesis Abnormal tumour angiogenesis significantly contributes to hypoxia and immunosuppression within the tumour microenvironment (TME). The newly formed blood vessels exhibit structural disorganisation and functional deficiencies, which impede the effective infiltration and delivery of immune cells and therapeutic agents, thereby severely diminishing the efficacy of immune checkpoint inhibitors (ICIs)42. Consequently, targeting signalling pathways such as vascular endothelial growth factor (VEGF) to “normalize” aberrant tumour vasculature has emerged as a classical strategy to enhance cancer immunotherapy. This approach aims to improve blood perfusion, alleviate hypoxia, and reshape the immune microenvironment42,43. Although clinically utilised anti-VEGF monoclonal antibodies, such as bevacizumab, can extend progression-free survival in certain patients, their impact on overall survival remains limited and is often accompanied by adverse effects, including hypertension and thrombosis. These observations highlight the constraints of single-target interventions44. This scenario presents a promising opportunity for traditional Chinese medicine (TCM), which possesses multi-component and multi-target regulatory properties, to facilitate synergistic intervention. Research indicates that active components in traditional Chinese medicine can regulate angiogenesis-related signalling networks through multiple pathways, thereby promoting the normalisation of tumour vascular structure and function. For instance, in a tumour endothelial cell (TEC) model derived from hepatocellular carcinoma, the combined extract of A. membranaceus (AM) and Curcuma Wenyujin (CW) exhibited significant inhibitory effects on TEC proliferation at a concentration of 0.18 mg/mL, which is the same dose at which AM alone demonstrated notable inhibitory effects. Additionally, both extracts significantly reduced the expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2) in the TEC model. At the concentration of 0.18 mg/mL, identified through CCK8 assay screening as the minimum effective dose for inhibiting TEC proliferation, AM and CW significantly enhanced the formation of more regular and stable tubular structures in endothelial cells, suggesting their potential to promote vascular normalisation. The molecular mechanism underlying this process is intricately associated with dual-phase regulation. Specifically, AM and CW significantly enhance the expression of the endothelial maturation marker CD34, which promotes endothelial cell maturation and vascular stability. Conversely, they markedly inhibit the expression of the hypoxia-inducible transcription factor HIF-1α, leading to a reduction in the release of its downstream pro-angiogenic factor VEGF and mitigating tumour-induced abnormal angiogenesis. This dual regulatory mechanism, characterised by “promoting maturation while suppressing abnormality”, serves as the fundamental molecular basis for the ability of AM and CW to achieve tumour vascular normalisation42. This finding implies that this herbal combination may facilitate vascular normalisation by targeting the HIF-1α-VEGF axis42,43. Concurrently, the screening and identification of key active components from a pharmacokinetic perspective is essential for elucidating the material basis of herbal medicine effects. Multidimensional pharmacokinetic studies demonstrated that after multiple doses of SMI (10 mL/kg/d, intraperitoneal injection), protopanaxadiol (Rd) saponin accumulated significantly in tumour tissues and tumour endothelial cells (TECs). Its AUC0-∞ in tumour tissues increased 10.53-fold compared to a single dose, and its concentration in TECs was markedly higher than in non-endothelial cells. Mechanistic studies indicated that Rd inhibits migration (88% inhibition at 50 μmol/L) and tubule formation (40 and 56% inhibition at 10 and 50 μmol/L, respectively) in human umbilical vein endothelial cells (HUVECs) under hypoxic conditions, while concurrently reducing VEGF and FGF secretion in tumour tissues (by 32 and 68%, respectively). This action results in significant anti-angiogenic and vascular normalisation effects. In vivo experiments further confirmed that Rd (5 mg/kg/d) reduced tumour microvascular density by 31%, decreased vascular branching by 59%, and increased pericellular coverage by 2.1-fold, thereby enhancing vascular structure and function. The selective enrichment of Rd in TECs, along with its multifaceted anti-angiogenic mechanisms, constitutes the molecular basis for its role as a key active component in SMI, mediating tumour vascular normalisation45. Collectively, these studies illustrate the potential of traditional Chinese medicine to achieve vascular normalisation by regulating critical signalling pathways and effector molecules, both at the level of the whole compound and its individual constituents. Traditional Chinese Medicine (TCM)-induced vascular normalisation offers several beneficial implications for reversing the immunosuppressive microenvironment associated with tumours. Improved vascular structure and function can significantly enhance tumour tissue perfusion and alleviate hypoxia, which subsequently downregulates the expression of various immunosuppressive factors, including HIF-1α43. Additionally, normalised blood vessels facilitate the more effective infiltration of immune effector cells, such as cytotoxic T lymphocytes, into the tumour core42. Consequently, by promoting vascular normalisation through multiple targets, TCM can disrupt the detrimental cycle of “hypoxia-abnormal vasculature-immunosuppression”. This process creates a better-perfused and less immunosuppressive microenvironment for immune checkpoint inhibitors (ICIs), thereby enhancing anti-tumour immune responses from both vascular remodelling and immunomodulation perspectives43. Targeting immune checkpoint signaling Traditional Chinese medicines can reverse the immunosuppressive state within the tumour microenvironment (TME) by directly modulating the expression of key immune checkpoint molecules on tumour and immune cells, thereby enhancing the efficacy of immune checkpoint inhibitors (ICIs). For instance, berberine (BBR), an isoquinoline alkaloid derived from traditional Chinese medicines such as Coptis chinensis, has been shown to exert antitumor effects as a small-molecule immune checkpoint modulator. Mechanistic studies reveal that BBR (10 μmol/L for 24 h) specifically binds to the JAMM domain of the deubiquitinating enzyme CSN5 (binding constant K_D = 16.25 μmol/L), with the critical binding site identified as the Glu76 residue. This interaction inhibits the deubiquitinating activity of CSN5, thereby obstructing its stabilising effect on PD-L1 and facilitating PD-L1 degradation through the ubiquitin-proteasome pathway. In non-small cell lung cancer cells (H460, H1975, etc.), BBR (5–20 μmol/L) dose- and time-dependently decreased PD-L1 protein levels (IC50 ∼8 μmol/L) without significantly impacting cell viability (survival rate >85%). In lung cancer xenograft models, BBR (4, 8 mg/kg/d intraperitoneal injection for 18 consecutive days) demonstrated a dose-dependent inhibition of tumour growth, achieving suppression rates of 46.8 and 75.8%, respectively. This effect was found to be T-cell dependent, as tumour suppression was absent in nude mice. BBR treatment resulted in a 1.8-fold increase in tumour-infiltrating CD8+ T cells, elevated the CD8+/CD4+ ratio, and significantly enhanced the presence of IFN-γ and granzyme B-positive CD8+ T cells. Additionally, BBR treatment reduced myeloid-derived suppressor cells and regulatory T cells by 52 and 41%, respectively. This study indicates that BBR enhances T cell antitumor immunity by targeting the CSN5-PD-L1 axis, thereby providing a molecular basis for its application as an adjunct to immune checkpoint inhibitor therapy in traditional Chinese medicine46. Compound traditional Chinese medicines exhibit potential for the multi-target regulation of immune checkpoints. For example, Xiaodu Shuan significantly inhibited the upregulation of immune checkpoint molecules on cytotoxic T lymphocytes (CTLs) induced by regulatory T cells (Tregs) in a co-culture system involving SiHa cervical cancer cells and T cells. In a 1:1 CTL-Treg co-culture system supplemented with 75% SiHa cervical carcinoma cell supernatant, the surface expression of CTLA-4 and PD-1 proteins on CTLs markedly increased. Following treatment with β-elemene (8 mg/L) and disinfection suppositories (2 mL/L), the levels of CTLA-4 and PD-1 proteins significantly decreased, with the disinfection suppository group demonstrating a more pronounced effect. This finding suggests that disinfection suppositories may enhance the local immune microenvironment by suppressing Treg function and downregulating the expression of inhibitory receptors on CTL surfaces31. Additionally, another classical formula, Gegen Qinlian Decoction (GQD), exhibited synergistic antitumor effects when combined with anti-PD-1 antibody therapy in a microsatellite-stable (MSS) colorectal cancer CT26 tumour-bearing mouse model. After 32 days of treatment with GQD (300 mg/kg/d via oral gavage) in conjunction with anti-PD-1 antibody (250 μg/mouse, administered intraperitoneally every 3 days), the tumour growth inhibition rate reached 70.526%, significantly surpassing that of the PD-1 monotherapy group. Mechanistic studies indicated that the combination therapy altered the gut microbiota structure, markedly enriching the beneficial bacteria Bacteroides acidifaciens and Bacteroidales_S24-7_group. Additionally, this treatment upregulated CD8+ T cell infiltration and interferon-γ (IFN-γ) levels in tumour tissues, downregulated PD-1 expression, and restored T cell function. These findings elucidate, at multiple levels, the molecular mechanisms by which traditional Chinese medicine formulas enhance the efficacy of immune checkpoint inhibitors by regulating immune cell surface checkpoints, gut microbiota, and the tumour immune microenvironment47. The results demonstrate that traditional Chinese medicine can synergistically modulate key immune checkpoints such as PD-1/PD-L1 and CTLA-4 through various components and pathways, thereby improving the immunosuppressive microenvironment and enhancing the therapeutic response to immune checkpoint inhibitors, as shown in Figure 2. Multidimensional mechanisms of traditional Chinese medicine (TCM) in remodelling the tumour immune microenvironment (TME) to enhance immune checkpoint inhibitor (ICI) efficacy. This figure depicts four primary mechanistic pathways through which TCM components, including single herbs, decoctions, and active monomers, modulate the TME. (A) Promoting immune cell infiltration and activation: TCM, such as Shenmai injection and Huanglian Jiedu Decoction, increases the infiltration of GZMAhigh NK cells, XCL1high NK cells, and CD8+ T cells while decreasing the presence of immunosuppressive cells, including Tregs and M2 macrophages. (B) Improving tumour hypoxia: TCM components, including cardamonin and ginsenosides, inhibit HIF-1α and its downstream effectors (PDHK1, LDHA), thereby shifting metabolism from glycolysis to oxidative phosphorylation and mitigating hypoxia-driven immunosuppression. (C) Inhibiting abnormal angiogenesis: Extracts from Astragalus and Curcuma, along with ginsenoside Rd, promote vascular normalisation by downregulating VEGF/VEGFR-2 and HIF-1α, enhancing pericyte coverage, and reducing vessel branching, which improves tumour perfusion and facilitates immune cell delivery. (D) Targeting immune checkpoint signalling: Berberine binds to the JAMM domain of CSN5, inhibiting its deubiquitinating activity and promoting PD-L1 degradation; other TCM formulations downregulate PD-1 and CTLA-4 expression on T cells. Collectively, these mechanisms counteract the immunosuppressive TME and enhance T cell-mediated antitumor immunity. Regulation of immune evasion in tumour cells Tumour cells constitute a fundamental element of the immune microenvironment. They evade immune detection through various mechanisms, such as downregulating antigen-presenting molecules, overexpressing immune checkpoint ligands, and secreting immunosuppressive factors. Active components of traditional Chinese medicine (TCM) can directly target tumour cells, reducing their capacity for immune evasion and thereby improving the effectiveness of immune checkpoint inhibitors (ICIs). Studies have demonstrated that berberine inhibits the deubiquitinase activity of CSN5, thereby diminishing its stabilising effect on PD-L1 and promoting PD-L1 degradation through the ubiquitin-proteasome pathway. This action effectively reduces the immunosuppressive signals emitted by tumour cells at their source46. Additionally, certain active components of traditional Chinese medicine (TCM) can enhance the expression of MHC class I molecules on tumour cells, thereby improving their antigen-presenting capacity. For instance, polysaccharides derived from A. membranaceus increase MHC-I expression on the surfaces of tumour cells by activating the STAT1 signalling pathway, which facilitates T cell recognition and cytotoxicity. Conversely, Ginsenoside Rh2 mitigates the functional inhibition of adjacent immune cells by reducing the secretion of immunosuppressive factors such as TGF-β and IL-10 from tumour cells. By directly modulating the expression of immune evasion-related molecules and the secretory functions of tumour cells, TCM diminishes the “camouflage” and “suppression” of the immune system by tumours at their origin. This action creates favourable conditions for immune checkpoint inhibitors (ICIs) to exert their therapeutic effects. Regulation of tumor stromal components Tumour stromal components, which include cancer-associated fibroblasts (CAFs), the extracellular matrix (ECM), vascular endothelial cells, and other elements, play a crucial role in forming the physical barrier and regulating metabolism within the immune microenvironment. Aberrantly activated CAFs secrete substantial quantities of ECM proteins and immunosuppressive factors, thereby creating a physical barrier that hinders T cell infiltration. Simultaneously, abnormal vascular structures result in inadequate perfusion and hypoxia, which further intensify immunosuppression. Traditional Chinese medicine (TCM) has the potential to remodel the tumour microenvironment by modulating these stromal components. For instance, the combination of A. membranaceus and Curcuma phaeocaulis (Ezhu) inhibits CAF activation, reduces collagen deposition, and lowers interstitial fluid pressure, thus enhancing T cell infiltration capacity42. Regarding vascular regulation, ginsenoside Rd, an active component of Shenmai Injection, selectively accumulates in tumour vascular endothelial cells, inhibits the secretion of VEGF and FGF, reduces abnormal vascular branching, and increases pericyte coverage. This process leads to vascular normalisation and improves tumour perfusion as well as the delivery of immune cells45. Additionally, certain TCM components can regulate the ECM degradation enzyme system; for example, baicalein inhibits the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9, remodels ECM structure, and facilitates immune cell penetration and migration. By modulating cancer-associated fibroblast (CAF) function, promoting vascular normalisation, and remodelling extracellular matrix (ECM) architecture, traditional Chinese medicine (TCM) systematically enhances the physical and metabolic barriers of the tumour stroma. This process establishes a microenvironmental foundation that facilitates effective immune cell infiltration and maximises the therapeutic potential of immune checkpoint inhibitors. Regulating gut microbiota homeostasis The relationship between gut microbiota and immunotherapy response Modulating gut microbiota homeostasis significantly enhances the efficacy of immune checkpoint inhibitors. The underlying mechanisms can be understood from two interrelated perspectives. The composition and function of the gut microbiota directly affect the body’s responsiveness to anti-tumour immunotherapy. Research indicates that specific beneficial microbiota, such as Faecalibacterium and Bifidobacterium, can improve the immune status of the tumour microenvironment by activating dendritic cells, enhancing CD8+ T cell infiltration, and reducing regulatory T cell activity, thereby increasing sensitivity to immune checkpoint inhibitors (ICIs) 48,49. The multi-component nature of traditional Chinese medicine (TCM) offers a unique advantage for regulating the microbiota. Active ingredients in TCM, including polysaccharides, flavonoids, and alkaloids, can selectively promote the growth of probiotics, inhibit the proliferation of conditional pathogens, and modulate the production of microbial metabolites, such as short-chain fatty acids and tryptophan metabolites. This modulation leads to the repair of the intestinal barrier, regulation of systemic immune responses, and ultimately fosters a microenvironment conducive to an effective immunotherapy response50,51. Consequently, microbiota modulation strategies mediated by TCM present a novel, multi-target, and holistic intervention approach to overcoming ICI resistance. Regulation of microbiota composition and metabolites by TCM components Research indicates that gut microbiota-based intervention strategies not only enhance the antitumor efficacy of immune checkpoint inhibitors but also assist in managing their immune-related adverse reactions. For example, Wang et al. reported the first successful treatment of two cases of refractory immune checkpoint inhibitor-associated colitis through faecal microbiota transplantation (FMT), providing direct clinical evidence for mitigating immunotherapy toxicity via microbiota modulation33. Both patients underwent one or two FMT sessions, receiving 50 g of donor stool infused via colonoscopy. Following the transplant, clinical symptoms and endoscopic inflammation significantly improved, with patients resuming regular bowel movements and discontinuing immunosuppressive therapy. Microbiome analysis indicated that post-FMT, the gut α-diversity and composition of the patients converged towards the donor profile, demonstrating successful colonisation by donor-derived bacteria, such as Bacteroides and Bifidobacterium. Immunohistochemical analysis revealed a decreased density of CD8+ T cells in the colonic mucosa, accompanied by a relative increase in CD4+ FoxP3+ regulatory T cells, suggesting that FMT may alleviate intestinal inflammation by reshaping the local immune balance33. Further mechanistic studies have shown that specific gut microbes and their metabolites play crucial roles in regulating antitumor immunity. The probiotic Lacticaseibacillus rhamnosus Probio-M9 (5 × 109 CFU daily via gavage), in conjunction with anti-PD-1 therapy (100 μg/mouse every 3 days), significantly enhanced antitumor efficacy in a CT26 colorectal cancer mouse model. Tumour volume decreased by ∼40% compared to the monotherapy group, and survival rates improved markedly52. Multi-omics analysis indicated that Probio-M9 intervention enriched beneficial bacteria, including Bifidobacterium animalis and Lactobacillus johnsonii, increased intestinal short-chain fatty acids (acetic, propionic, and butyric acids), and elevated serum levels of immunomodulatory molecules such as α-ketoglutarate, N-acetyl-L-glutamate, and pyridoxal. These metabolic changes promoted CD8+ T cell infiltration, resulting in a ∼1.5-fold increase, and enhanced IFN-γ expression within the tumour microenvironment while reducing the proportions of FoxP3+ regulatory T cells. This interplay ultimately enhanced the antitumor efficacy of anti-PD-1 therapy52. These findings support the hypothesis that gut microbiota composition and function directly influence the response to immunotherapy. Exogenous interventions, such as probiotics and faecal microbiota transplantation (FMT), can optimise therapeutic efficacy by reshaping the “microbiota-metabolite-immune” axis, thereby offering novel strategies to overcome immunotherapy resistance and mitigate adverse effects53. The microbial regulation strategies outlined above closely align with the multi-component, systemic regulatory characteristics of traditional Chinese medicine (TCM). This alignment provides both theoretical and preclinical foundations for enhancing TCM-based immunotherapy while reducing its toxicity. Research demonstrates that multiple active components in TCM can alleviate intestinal inflammation and related diseases by modulating the gut microbiota and its metabolites. For example, in a mouse model of acute ulcerative colitis induced by dextran sulphate sodium (2.5% DSS in drinking water for 7 days), ginsenoside Rg1 administered via oral gavage at a dose of 2 mg/10 g body weight (equivalent to 20 mg/kg) significantly mitigated colonic damage and inflammation54. The underlying mechanism involves modulating gut microbiota composition, increasing the relative abundances of norank_f_Muribaculaceae, Lactobacillus, Allobaculum, and Akkermansia, while decreasing the levels of Odoribacter, Clostridium UCG-014, Bacteroides, and Turicibacter. Additionally, Rg1 modulates microbial tryptophan metabolism, which significantly elevates serum levels of aromatic receptor ligands such as indole-3-carboxaldehyde, indole-3-lactic acid, and 3-indolepropionic acid, as well as nicotinamide, thereby enhancing intestinal barrier function54. Beyond its localised effects in the intestine, Rg1 exhibits broad-spectrum anti-inflammatory actions through multi-target mechanisms. In various models of inflammation-related diseases, including neuroinflammation, liver injury, and diabetes, Rg1 (administered at common in vivo doses of 10–50 mg/kg) suppresses oxidative stress and inflammasome activation by regulating the NLRP3/Nrf2 signalling pathways55. The specific mechanism involves the promotion of Nrf2 nuclear translocation and the expression of downstream targets HO-1 and NQO1, while concurrently inhibiting NLRP3 inflammasome assembly and the release of pro-inflammatory factors such as IL-1β and IL-633. In a mouse model of colitis-associated tumours induced by AOM/DSS (a single intraperitoneal injection of AOM at 10 mg/kg combined with 2.75% DSS in drinking water), oral administration of Ganoderma lucidum polysaccharides (GLP) at doses of 200 and 300 mg/kg significantly reduced colonic inflammatory responses and inhibited tumorigenesis, as evidenced by decreased tumour number and volume56. The mechanism exhibits multi-target characteristics: ① Modulating gut microbiota composition by increasing the abundance of probiotic genera such as Lactobacillus and Bifidobacterium while decreasing opportunistic pathogens like Oscillibacter and Desulfovibrio; ② Elevating faecal short-chain fatty acid (SCFA) levels, particularly propionic and butyric acids; ③ Alleviating endotoxemia by inhibiting the TLR4/MyD88/NF-κB signalling pathway; ④ Strengthening intestinal barrier function through increased goblet cell numbers, MUC2 secretion, and the expression of tight junction proteins ZO-1 and Occludin; ⑤ Inhibiting macrophage infiltration and the expression of inflammatory mediators, including iNOS, COX-2, and IL-1β; ⑥ In vitro, GLP suppresses MAPK (JNK and ERK) phosphorylation in LPS-stimulated RAW264.7 macrophages, HT-29, and NCM460 intestinal epithelial cells, thereby blocking the amplification of inflammatory signals56. These studies provide experimental evidence that the active components of traditional Chinese medicine enhance the tumour microenvironment and improve immune surveillance by regulating gut microbiota and its metabolism, thereby intervening in multiple inflammatory signalling pathways. Gegen Qinlian Decoction, when administered in conjunction with anti-PD-1 antibody, exhibited synergistic antitumor effects in a CT26 tumour-bearing mouse model of microsatellite-stable (MSS) colorectal cancer. This combination therapy achieved a tumour inhibition rate of 70.526%, significantly surpassing the efficacy of anti-PD-1 monotherapy. Mechanistic investigations indicated that the combination therapy altered the gut microbiota structure, markedly enriching beneficial bacterial populations such as Bacteroides acidifaciens and the Bacteroidales_S24-7_group. Additionally, it upregulated CD8+ T cell infiltration and IFN-γ levels in tumour tissue while downregulating PD-1 expression, thereby restoring T cell function47. Moreover, ginseng polysaccharide, when combined with anti-PD-1/PD-L1 therapy, enhanced antitumor immune responses by modulating the gut microbiota and the kynurenine/tryptophan ratio26. Ganoderma lucidum polysaccharide, through the regulation of gut microbiota composition by enriching Lactobacillus and Bifidobacterium species, as well as by enhancing immune cell function through an increased proportion of CD8+ T cells and a reduction in myeloid-derived suppressor cell levels, synergistically improved the efficacy of both chemotherapy and immunotherapy56. Collectively, these studies illustrate that traditional Chinese medicine can systematically enhance the antitumor efficacy of immune checkpoint inhibitors via the “microbiota-metabolite-immune” axis, thereby providing a compelling rationale for the integration of TCM and immunotherapy in cancer treatment. The aforementioned studies indicate that the active components of traditional Chinese medicine (TCM) can significantly modulate the composition and diversity of gut microbiota. However, alterations in the microbiota are not the ultimate effector link; rather, the regulation of host immunity and the enhancement of immune checkpoint inhibitors (ICIs) are primarily mediated by microbiota-derived metabolites. Recent research has demonstrated that TCM influences the abundance of specific microbial populations, which in turn affects the production of three major classes of microbial metabolites, thereby forming the core mechanism of the “microbiota-metabolite-immune” axis. Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are critical metabolites produced by gut microbiota through the fermentation of dietary fibre. TCM polysaccharides can significantly enrich SCFA-producing bacteria, such as Bifidobacterium, Lactobacillus, and Faecalibacterium species. SCFAs enhance the cytotoxic function of CD8+ T cells while simultaneously suppressing the immunosuppressive activity of regulatory T cells by acting on G protein-coupled receptors and inhibiting histone deacetylases56. Secondary bile acids are produced from primary bile acids through biotransformation by gut microbiota. Traditional Chinese Medicine (TCM) can alter the metabolic profile of secondary bile acids, including lithocholic acid and deoxycholic acid, by modulating the abundance of bacterial genera such as Clostridium and Bacteroides. These secondary bile acids regulate the antigen-presenting function of dendritic cells and enhance antitumor immune responses by interacting with the farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor 5 (TGR5) 28. Tryptophan metabolites, such as indole-3-propionic acid and indole-3-carboxaldehyde, serve as important ligands for the aryl hydrocarbon receptor (AhR). Active components of TCM can reshape the tryptophan metabolic profile by influencing the abundance of tryptophan-metabolizing bacteria, including Lactobacillus and Clostridium cluster XIVa. The activation of the AhR signalling pathway promotes dendritic cell maturation, enhances intestinal barrier function, and facilitates the infiltration and function of CD8+ T cells54. In summary, traditional Chinese medicine (TCM) systematically influences the host’s systemic immune status through a cascade mechanism defined by “modulating microbiota structure → reshaping metabolite profiles → regulating immune responses”. This “microbiota-metabolite-immune” axis provides critical mechanistic insights into how TCM enhances the efficacy of immune checkpoint inhibitors (ICIs). The potential application of traditional Chinese medicine in mitigating ICI toxicity Immune checkpoint inhibitors (ICIs) have shown considerable efficacy in anti-tumour therapy; however, the immune-related adverse events (irAEs) they provoke significantly restrict their widespread clinical use. irAEs can impact various organ systems, with certain events posing life-threatening risks. Grounded in the principles of holistic regulation and treatment based on syndrome differentiation, Traditional Chinese Medicine (TCM) presents distinctive potential for mitigating irAEs. Its mechanisms of action encompass multiple pathways, including the modulation of immune-inflammatory responses, enhancement of gut microbiota, reduction of oxidative stress, and preservation of organ function. Prevention and treatment of immune-related colitis ICI-induced colitis (ICIIC) is a prevalent immune-related adverse event (irAE). Its pathogenesis is closely linked to abnormal gastrointestinal immune inflammation and dysbiosis of the intestinal microbiota27. Current clinical management primarily employs immunosuppressants, such as corticosteroids; however, their efficacy is inconsistent, and prolonged use may exacerbate immunosuppression57. Traditional Chinese Medicine (TCM) offers a novel approach for the prevention and treatment of ICIIC by regulating immune cell balance and intestinal microecology58. Classic formulas, such as Scutellaria Decoction, administered orally at a dosage of 9.5 g/kg in a TNBS-induced colitis mouse model, significantly ameliorate colonic inflammation. The mechanism of action involves the regulation of CD4+ T cell subset balance, specifically by suppressing the activation and proliferation of effector T cells (e.g. Th1/Th17) while promoting the differentiation and function of regulatory T cells (Treg), thereby restoring intestinal immune homeostasis10. Additionally, in a DSS-induced ulcerative colitis mouse model, modified Bai Tou Long Tang administered at 8.4 g/kg via oral gavage alleviated colonic tissue damage and inflammatory responses. This effect was achieved by modulating gut microbiota composition (e.g. increasing the abundance of probiotics like Lactobacillus spp. and reducing opportunistic pathogens) and altering its metabolite profile (e.g. short-chain fatty acids and bile acid metabolic pathways) 59. These studies suggest that traditional Chinese medicine formulas can provide preventive and therapeutic benefits for immune checkpoint inhibitor-associated colitis by regulating the immune-microbiome network, influencing T cell subset differentiation, and maintaining intestinal microecological balance. Alleviating cardiotoxicity Despite the low incidence of immune checkpoint inhibitor (ICI)-associated myocarditis, its high fatality rate renders it a serious immune-related adverse event (irAE) that requires urgent attention in clinical practice60. Current research is constrained by preclinical models; however, existing studies indicate that traditional Chinese medicine (TCM) may provide cardioprotective effects via mechanisms such as antioxidant activity and the inhibition of cell death. Cyanidin chloride demonstrates substantial protective effects in a model of adriamycin-induced cardiac toxicity. In zebrafish models, doses between 5 and 20 μM significantly enhance cardiac function, while in H9c2 cardiomyocytes, pre-treatment with 2.5–10 μM markedly reduces adriamycin-induced cellular damage. The underlying molecular mechanism involves competitive binding to the KEAP1 protein, as confirmed by molecular docking and surface plasmon resonance (SPR) experiments, yielding a Kd value of 11.3 μM. This interaction activates NRF2 and promotes the expression of its downstream target gene GPX4, which subsequently inhibits lipid peroxidation and mitochondrial damage, ultimately preventing ferroptosis and apoptosis in cardiomyocytes61. In a mouse model of adriamycin-induced cardiac toxicity, oral administration of glycyrrhetinic acid at a dose of 40 mg/kg significantly improved indicators of cardiac function and decreased serum levels of cardiac enzymes. The mechanism of action involves the upregulation of the Nrf2/HO-1 signalling pathway, suppression of oxidative stress markers, including malondialdehyde and reactive oxygen species, and a reduction in cardiomyocyte apoptosis, as confirmed by TUNEL staining and the expression of apoptosis-related proteins Bax and Bcl-262. These findings suggest that active components of traditional Chinese medicine can inhibit oxidative stress, ferroptosis, and apoptosis by targeting endogenous antioxidant pathways such as KEAP1-NRF2-GPX4 and Nrf2/HO-1, thereby providing potential strategies for the prevention and treatment of immune checkpoint inhibitor-related cardiac toxicity. The application of traditional Chinese medicine (TCM) in mitigating immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) can be categorised into two modes based on the timing of intervention: prophylactic administration and therapeutic administration. These modes differ markedly in their mechanisms of action and clinical positioning. Mechanistic characteristics of prophylactic administration Prophylactic administration refers to the intervention of traditional Chinese medicine (TCM) implemented before or concurrently with immune checkpoint inhibitor (ICI) therapy, with the objective of mitigating the risk of immune-related adverse events (irAEs) by pre-emptively regulating immune homeostasis. The primary mechanism centres on the establishment and maintenance of immune tolerance. In models of colitis, the prophylactic use of formulations such as Huangqin Tang (Scutellaria Decoction) has been shown to decrease the incidence of ICI-induced intestinal inflammation by promoting the differentiation and function of regulatory T cells (Tregs), enhancing the integrity of the intestinal mucosal barrier, and suppressing the excessive activation of effector T cells60. In the context of cardiotoxicity, the prophylactic administration of active components, such as anthocyanins, enhances the tolerance of cardiomyocytes to oxidative stress and diminishes susceptibility to immune-related myocardial injury by activating the NRF2/HO-1 antioxidant pathway61. The advantage of prophylactic administration lies in its ability to “prevent the problem before it occurs”; however, it necessitates a clearly defined intervention window and careful consideration to avoid potential interference with the antitumor efficacy of ICIs. Mechanistic characteristics of therapeutic administration Therapeutic administration refers to the intervention of traditional Chinese medicine (TCM) implemented after the onset of immune-related adverse events (irAEs), with the objective of suppressing the inflammatory response and promoting tissue repair. This mechanism emphasises the synergistic effects of anti-inflammatory and immunomodulatory actions. In cases of established immune checkpoint inhibitor (ICI)-associated colitis, the therapeutic administration of formulas such as Baitouweng Tang (Pulsatilla Decoction) effectively controls intestinal inflammation by inhibiting the NF-κB signalling pathway, downregulating the expression of pro-inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6), and modulating the gut microbiota-metabolite axis. In instances of established cardiotoxicity, the therapeutic administration of components such as glycyrrhetinic acid demonstrates cardioprotective effects by inhibiting NLRP3 inflammasome activation and reducing cardiomyocyte apoptosis and ferroptosis61. The primary advantage of therapeutic administration lies in its ability to “prevent progression after disease onset”; however, careful consideration must be given to the timing and dosage of administration to achieve an optimal risk-benefit balance. In summary, a clear distinction between prophylactic and therapeutic administration modes is essential for developing individualised TCM combination regimens in clinical practice, tailored to different intervention goals, thereby maximising the safety window of ICI therapy. Future research should conduct head-to-head comparative studies targeting various intervention timings to provide more precise evidence to support clinical decision-making. TCM approaches for mitigating other irAEs In addition to colitis and myocarditis, immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) across multiple organ systems. Utilising its multi-system regulatory capabilities, Traditional Chinese Medicine (TCM) demonstrates potential in mitigating these adverse reactions. Components of TCM with immunomodulatory properties can attenuate inflammation and tumorigenesis by modulating gut microbiota and immune cell functions63. Ganoderma lucidum polysaccharides (GLP) act as adjuvant agents in cancer therapy, exhibiting antitumor effects through immune function modulation. In a mouse model of S-180 sarcoma, oral administration of GLP at doses ranging from 100 to 400 mg/kg over 20 days resulted in tumour inhibition rates of 53–59%. This outcome correlated with increased serum levels of IL-2 and TNF-α, as well as heightened proportions of CD8+ T cells, indicating that tumour suppression is mediated by enhanced cellular immunity rather than direct cytotoxicity against tumour cells. In T24 tumour-bearing nude mouse models, the combination of GLP (200 mg/kg) and cisplatin treatment over 18 days significantly elevated the spleen index and increased the proportions of CD4+, CD8+ T cells, natural killer (NK) cells, and dendritic cells in both the spleen and peripheral blood. Concurrently, this treatment reduced levels of myeloid-derived suppressor cells and enhanced the expression of IL-2 and TNF-α. This suggests that GLP enhances the efficacy of chemotherapy by improving immune cell function and reducing immune escape27. In a mouse model of irinotecan-induced colitis, oral administration of total flavonoids from Glycyrrhiza (TFGU) at a dose of 80 mg/kg significantly alleviated weight loss and colon shortening, decreased the disease activity index, and lowered colonic histopathology scores. The underlying molecular mechanism involves the regulation of gut microbiota composition, notably by increasing Lactobacillus abundance, and reversing irinotecan-induced faecal metabolic disorders, particularly through the normalisation of xanthine and uric acid levels. This process inhibits NLRP3 inflammasome activation and downstream inflammatory factors, including TNF-α, IL-1β, and IL-664. These studies illustrate that the active components of traditional Chinese medicine provide comprehensive protective effects against multisystem immune-related adverse events by systemically regulating immune homeostasis—enhancing effector cell function while suppressing immunosuppressive cells—and modulating the intestinal microenvironment through alterations in microbiota composition and metabolic products, as shown in Figure 3. Traditional Chinese medicine (TCM) modulates gut microbiota to enhance immune checkpoint inhibitor (ICI) responses and alleviate immune-related adverse events (irAEs). The left panel illustrates that TCM components, such as Ganoderma lucidum polysaccharides, ginsenoside Rg1, and Gegen Qinlian Decoction, reshape gut microbiota composition by increasing the abundance of beneficial bacteria, including Bifidobacterium, Lactobacillus, Faecalibacterium, and Akkermansia, while decreasing opportunistic pathogens. These microbial alterations result in modified production of key metabolites, including short-chain fatty acids (SCFAs; e.g. butyrate, propionate), secondary bile acids (e.g. lithocholic acid, deoxycholic acid), and tryptophan metabolites (e.g. indole-3-propionic acid, indole-3-aldehyde). These metabolites engage distinct receptors, such as GPR41/GPR43 for SCFAs, FXR/TGR5 for bile acids, and AhR for tryptophan metabolites, to enhance CD8+ T cell infiltration and function, promote dendritic cell maturation, and reduce regulatory T cell activity, thereby potentiating ICI efficacy. The right panel indicates that TCM also mitigates ICI-induced irAEs, such as colitis, by restoring intestinal barrier integrity through the upregulation of tight junction proteins ZO-1 and occludin, reducing local inflammation via the downregulation of TNF-α, IL-1β, and IL-6, and promoting regulatory T cell differentiation. This figure emphasises the “microbiota-metabolite-immunity” axis as a central mechanism through which TCM synergizes with ICIs. Discussion This article systematically reviews the dual role of Traditional Chinese Medicine (TCM) as an adjunctive therapeutic strategy to Immune Checkpoint Inhibitors (ICIs), focusing on its efficacy enhancement and toxicity reduction, as well as the underlying mechanisms involved. By leveraging its holistic regulatory properties, which are characterised by multiple components, targets, and pathways, TCM effectively reverses ICI resistance and enhances anti-tumour immune responses. This is achieved through the remodelling of the tumour immune microenvironment, which includes regulating immune cells, ameliorating hypoxia, inhibiting abnormal angiogenesis, and intervening in checkpoint signalling, as well as modulating gut microbiota homeostasis65. Additionally, TCM exhibits multi-pathway potential in preventing and alleviating multi-system immune-related adverse events (irAEs) induced by ICIs, particularly colitis and cardiotoxicity, due to its anti-inflammatory, antioxidant, and organ-protective effects8,10. This underscores the unique value of TCM’s holistic perspective and its treatment approach based on syndrome differentiation in addressing the complex challenges associated with modern tumour immunotherapy. In addition to the mechanisms previously discussed, recent studies have demonstrated that the heterogeneity of the intratumoral microbial community significantly influences tumour development and response to immunotherapy. Unlike the gut microbiota, the intratumoral microbiota exhibits considerable spatial heterogeneity and specificity across tumour types. Its composition and functional status can directly affect local immune cell infiltration, the efficiency of antigen presentation, and the expression of immune checkpoint molecules, thereby shaping the immunosuppressive tumour microenvironment66. A comprehensive understanding of the distribution characteristics of intratumoral microorganisms and their interaction networks with host immune cells may reveal new intervention targets to address resistance to immune checkpoint inhibitors. The induction of immunogenic cell death (ICD) has emerged as a pivotal strategy for activating antitumor immune responses, garnering significant attention. ICD facilitates dendritic cell maturation and antigen cross-presentation through the release of damage-associated molecular patterns (DAMPs), including calreticulin, high-mobility group box 1 (HMGB1), and ATP. This process initiates tumour-specific T cell responses, transforming “cold” tumours into “hot” tumours and effectively reversing the immunosuppressive tumour microenvironment67. Recent studies have shown that certain active components of traditional Chinese medicine (TCM), such as berberine, ginsenosides, and curcumin, can induce tumour cell apoptosis while concurrently activating ICD-related signalling pathways. This suggests their potential for synergistic combination with immune checkpoint inhibitor (ICI) therapy68. This finding offers a novel theoretical framework for TCM to enhance ICI efficacy through the dual mechanisms of inducing immunogenic cell death and reshaping the immune microenvironment. The regulation of intratumoral microbiota heterogeneity and the induction of immunogenic cell death represent leading areas of current mechanistic research in tumour immunotherapy. Future investigations may focus on the specific targets and signalling networks associated with the active components of traditional Chinese medicine (TCM) within these two domains. This approach could facilitate the development of a more systematic and multidimensional integrative intervention system that combines TCM with immunotherapy. Based on the mechanistic analysis presented, we propose that the application strategies of traditional Chinese medicine (TCM) in immune checkpoint inhibitor (ICI) therapy can be optimised across four dimensions to better achieve the clinical objective of “enhancing efficacy while reducing toxicity”: (1) Precision: Biomarker-guided TCM combination strategies. Current research on TCM in conjunction with ICI therapy predominantly employs a “one-size-fits-all” methodology, which lacks precise stratification for distinct patient populations. Future TCM intervention regimens should be tailored based on biomarkers, including tumour mutational burden (TMB), microsatellite instability (MSI) status, PD-L1 expression levels, and gut microbiota characteristics. For patients with microsatellite-stable (MSS) colorectal cancer, Traditional Chinese Medicine (TCM) formulas that modulate the gut microbiota, such as Gegen Qinlian Decoction, may be preferentially chosen. In the case of patients with high tumour mutational burden (TMB), TCM monomers that directly influence PD-L1 expression, such as berberine, may be combined to achieve individualised precision compatibility. (2) Standardisation: It is essential to establish a quality control system for TCM in conjunction with immune checkpoint inhibitor (ICI) therapy. The “multi-component, multi-target” nature of TCM presents both advantages and challenges for standardisation. A comprehensive quality control standard should be developed, encompassing crude herb sourcing, extraction processes, and finished products, to ensure the stability and consistency of active components. Simultaneously, pharmacokinetics-based studies should be conducted to optimise compatibility, defining the ideal dosage, timing, and duration of TCM active components when used alongside ICIs. This approach will help avoid pharmacokinetic interactions that could undermine ICI efficacy or elevate toxicity risks. (3) Synergy: It is crucial to optimise the spatiotemporal dimensions of combination regimens. Prophylactic and therapeutic administrations exhibit significant differences in their mechanisms and should be clearly distinguished in clinical practice. Prophylactic administration should prioritise the establishment of immune tolerance and may be initiated prior to ICI treatment to mitigate the incidence of immune-related adverse events (irAEs). Therapeutic administration prioritises rapid anti-inflammatory effects and tissue repair, necessitating prompt initiation following the occurrence of immune-related adverse events (irAEs). Additionally, the sequence and timing of administration should be strategically organised based on the functional characteristics of traditional Chinese medicine (TCM) active components to optimise synergistic effects. For instance, TCM formulas that promote vascular normalisation, such as A. membranaceus combined with Curcuma phaeocaulis (Ezhu), may be administered before immune checkpoint inhibitors (ICIs) to enhance tumour perfusion and facilitate immune cell infiltration, thereby establishing a favourable microenvironment for subsequent ICI therapy. (4) Modernisation involves improving targeting through contemporary drug delivery technologies. Traditional TCM administration routes, including oral and intraperitoneal injection, often exhibit low bioavailability and non-specific tissue distribution. Future endeavours may investigate the integration of TCM active components with advanced technologies, such as nanodrug delivery systems and antibody-drug conjugates, to achieve selective targeting of the tumour microenvironment or immune cells. For example, berberine-loaded nanoparticles, with their enhanced tumour targeting and controlled release properties, could significantly improve PD-L1 degradation efficiency while minimising potential adverse effects associated with systemic exposure. By implementing the optimisation strategies delineated across these four dimensions, the integration of traditional Chinese medicine with immune checkpoint inhibitor therapy is anticipated to evolve from empirical application to a novel paradigm defined by precision, standardisation, synergy, and modernisation. This transition aims to offer a more clinically valuable integrated approach to cancer immunotherapy. Future research should prioritise an in-depth analysis of the specific molecular networks and cellular interaction mechanisms that underlie the synergistic effects of traditional Chinese medicine (TCM) and immune checkpoint inhibitors (ICIs). The utilisation of advanced technologies, including single-cell sequencing, spatial transcriptomics, metabolomics, and integrated multi-omics analysis, is crucial for systematically elucidating how active TCM components dynamically regulate the functional states and communication of diverse immune cell subsets within the tumour microenvironment (TME). Additionally, it is imperative to accurately decode the tripartite interaction among “TCM components-gut microbiota-host immunity” 65. Furthermore, enhancing pharmacokinetic and pharmacodynamic studies of TCM formulas and active constituents within the framework of combination therapy is necessary. Employing advanced models, such as organoids and organ-on-a-chip, will clarify their in vivo dynamics, target organ distribution, and biotransformation, thereby providing a scientific foundation for optimising dosing regimens. The primary objective is to facilitate the clinical translation and standardised application of combined Traditional Chinese Medicine (TCM) and immune checkpoint inhibitor (ICI) therapy. There is an urgent necessity for well-designed, large-scale, multi-center, high-quality clinical studies to generate robust evidence-based medical data that elucidate the efficacy, safety, and optimal application models of combination regimens for specific cancer types. Concurrently, it is essential to develop a comprehensive quality control standard system that encompasses the entire process, from TCM raw materials and preparation methods to the final product, thereby ensuring the stability and uniformity of pharmacologically active substances. By integrating mechanistic research, clinical validation, and quality control standards, there exists the potential to establish and promote a novel paradigm of individualised integrated Chinese-Western medicine for tumour immunotherapy, which aims to enhance efficacy while minimising toxicity, ultimately providing patients with safer and more effective treatment options.